BioSpace News Archive

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced that David O’Toole, Chief Financial Officer, will present at TD Cowen’s 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time.

S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for Phase 1/2a study for treating Parkinson’s disease.

Planet Labs PBC (NYSE:PL), a leading provider of daily data and insights about Earth, today announced that it plans to release its fiscal fourth quarter and full year 2024 financial results for the year that ended January 31, 2024, after market close on Thursday, March 28, 2024.

Alamar Biosciences is pleased to announce a strategic supply agreement with ALZpath, a leading developer of diagnostic solutions in Alzheimer’s disease and related dementias.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 11:10 a.m. Eastern Time.

Atara Biotherapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ATA3219.

For people with stroke, social factors such as education, neighborhood and employment may be linked to whether they receive treatment with clot-busting drugs, according to a preliminary study released February 28, 2024, that will be presented at the American Academy of Neurology’s 76th Annual Meeting taking place April 13–18, 2024, in person in Denver and online.

Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the FLC Kappa & Lambda assays.

As March approaches, the National Kidney Foundation is gearing up to observe National Kidney Month, a crucial time dedicated to raising awareness about kidney health and chronic kidney disease.

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the twelve months ended December 31, 2023.